Figure legends
Figure 1. Study flow chart.
SCIT: subcutaneous immunotherapy; V0: patients at the first visit; V1:
patients at 1-year follow up; VAS: visual analogue scale; dSS: daily
symptom score; dMS: daily medication score; CSMS: combined symptom and
medication scores; QoL: quality of life; SAS: self-rating anxiety scale;
SDS: self-rating depression scale.
Figure 2. Clinical manifestations in patients with scheduled and delayed
SCIT.
(A-E), Mean values with 25th and 75th percentiles are indicated by scale
bar. ****P < 0.0001, ***P < 0.001, **P <
0.01, *P < 0.05.
SCIT: subcutaneous immunotherapy; VAS: visual analogue scale; dSS: daily
symptom score; dMS: daily medication score; CSMS: combined symptom and
medication scores; QoL: quality of life; V0: patients at the first
visit; V1: patients at 1-year follow up.
Figure 3. Emotional evaluation of different diseases and SCIT among
patients in this study.
(A-B), Compared SAS and SDS of delayed SCIT group at V1, to delayed SCIT
group and V0, scheduled SCIT group at V0 and V1 in this study and
different diseases. Mean values with SD are indicated by scale bar.
(C), Proportion of SDS in patients with scheduled or delayed scheduled
or delayed at V0 and V1. Mean values with 25th and 75th percentiles are
indicated by scale bar.
(D), Correlation of SDS with time interval in the delayed SCIT group at
V0.
****P < 0.0001, ***P < 0.001, **P < 0.01,
*P < 0.05.
SCIT: subcutaneous immunotherapy; SAS: self-rating anxiety scale; SDS:
self-rating depression scale; COVID-19: coronavirus disease 2019; AR:
allergic rhinitis; CRS: chronic rhinosinusitis; SD: standard deviation;
RT:radiotherapy; V0: patients at the first visit; V1: patients at 1-year
follow up.
Figure 4. Compared clinical manifestations and control to depressive
symptoms.
(A-E), Compared VAS, dSS, dMS, CSMS, and QoL of SCIT patients in
non-depressed group to depressed group at V0 and V1. Mean values with
25th and 75th percentiles are indicated by scale bar. ****P <
0.0001, ***P < 0.001, **P < 0.01, *P <
0.05.
(F), Compared clinical control of SCIT patients to depressive symptom at
V0 and V1. Mean values with 25th and 75th percentiles are indicated by
scale bar. ***P < 0.001, **P < 0.01, *P <
0.05.
SCIT: subcutaneous immunotherapy; VAS: visual analogue scale; dSS: daily
symptom score; dMS: daily medication score; CSMS: combined symptom and
medication scores; QoL: quality of life; SDS: self-rating depression
scale; V0: patients at the first visit; V1: patients at 1-year follow
up.